Sign In
Buy FBIO
$2.61
-0.0400 (-1.51%)
At Close: Jun 03, 2026
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
08:00am, Monday, 23'rd Feb 2026
ATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy MIAMI, Feb. 23, 2026 (GLOBE NEW
Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap
09:38pm, Thursday, 19'th Feb 2026
Fortress Biotech is essentially a holding company biotech with a dermatology revenue base (Journey Medical). However, FBIO's subsidiaries give it optionality across multiple subsidiaries, equity stake
Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average – Here’s What Happened
04:17am, Thursday, 19'th Feb 2026
Fortress Biotech, Inc. (NASDAQ: FBIO - Get Free Report) shares crossed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $3.04 and
Fortress Biotech (NASDAQ:FBIO) Shares Pass Above 200-Day Moving Average – What’s Next?
03:24am, Tuesday, 03'rd Feb 2026
Fortress Biotech, Inc. (NASDAQ: FBIO - Get Free Report) shares crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $2.92 and traded as high as
Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission
08:00am, Monday, 15'th Dec 2025
MIAMI, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that the
Clinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on sk
Fortress Biotech (FBIO) Surpasses Q3 Earnings Estimates
10:41am, Friday, 14'th Nov 2025
Fortress Biotech (FBIO) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of a loss of $0.43 per share. This compares to a loss of $0.76 per share a year ago.
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
08:30am, Friday, 14'th Nov 2025
Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received
Fortress Biotech, Inc. (FBIO) Q3 2025 Earnings Call Transcript
10:41pm, Wednesday, 12'th Nov 2025
Fortress Biotech, Inc. ( FBIO ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Jaclyn Jaffe - Senior Director of Corporate Operations Claude Maraoui - Founder, President, CEO
Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
04:01pm, Wednesday, 12'th Nov 2025
Third quarter 2025 net revenues were $17.6 million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call to
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
07:00am, Thursday, 06'th Nov 2025
MIAMI, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization
Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025
08:30am, Wednesday, 05'th Nov 2025
Company to host conference call to discuss financial results and provide a corporate update on November 12, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provid
Fortress Biotech (NASDAQ:FBIOP) Stock Price Down 1.9% – Time to Sell?
02:49am, Tuesday, 04'th Nov 2025
Fortress Biotech, Inc. (NASDAQ: FBIOP - Get Free Report)'s share price was down 1.9% during mid-day trading on Monday. The stock traded as low as $6.80 and last traded at $6.87. Approximately 7,918 sh
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortress Biotech Inc. - FBIO
10:00am, Tuesday, 28'th Oct 2025
NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fortress Biotech Inc. ("Fortress" or the "Company") (NASDAQ: FBIO). Such investors are advised
